Physicians are aware that up to 50% of patients who are prescribed aspirin, Plavix® or other anti-platelet medications have little or no response to the therapy. This leaves patients at risk for an adverse cardiac event. To help physicians determine therapy efficacy, PlaCor developed a technology to measure the effectiveness of anti-platelet drugs to inhibit the clot formation that can result in heart attack or stroke.

PlaCor partnered with Minnetronix for product design, verification and scale-up to manufacturing. Minnetronix engineers worked on the sensing system, optical design, software, hardware and electronics design. Minnetronix also took on the mechanical design, and developed the feasibility prototype as well as the production-ready console. Throughout the development process, PlaCor relied upon the established Minnetronix quality system to ensure quality and documentation requirements were met. This allowed PlaCor to focus on broader business and product development opportunities, without having to implement new processes and systems.